InVentiv Health to buy SDI audits from IMS

Share this article:

Privately held inVentiv Health will acquire two of SDI Health's audit businesses worth under $15 million, according to company statements. IMS Health agreed to divest the units when regulators approved its purchase of SDI last year.


The promotional and medical audit businesses will be incorporated into the offerings of inVentiv Health's Campbell Alliance biopharma management consulting unit.


"This is an important step in boosting inVentiv's capabilities in market research and analytics," said Paul Meister, CEO, inVentiv Health, in a statement.


Campbell Alliance already has a market research and analytics group offering a range of longitudinal de-identified patient and prescription data and analytics services. The firm will combine the acquired business with the group, which also provides custom quantitative research, qualitative market research, and key opinion leader identification and mapping.


The deal follows IMS Health's acquisition of SDI Health, formally approved October 31, after which its parent company, Healthcare Technology Holdings, moved forward to divest the two SDI product lines, as per a settlement order proposed by the Federal Trade Commission to preserve competition.


In the settlement order, the FTC had required IMS to sell the two businesses to a buyer within three months of the completion of the deal, or Jan. 31, 2012.


Financial terms were not disclosed, but in a statement about yesterday's sale to inVentiv, IMS revealed that, under the two businesses it divested are a number of different data products, 11 to be exact. These products, which needed to be sold off to satisfy the FTC requirements, represent less than $15 million, or about 10% of SDI's 2011 revenue.

IMS will continue to market its existing medical and promotional services worldwide, the firm said, including the company's National Disease and Therapeutic Index (NDTI) and Integrated Promotional Services (IPS) offerings in the US.

"With the acquisition of SDI, IMS continues to build more innovative and comprehensive capabilities in the patient and payer spaces, consistent with the company's strategy to significantly expand its business in healthcare information, technology and services," IMS concluded.
Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

MM&M Future Leaders

Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 


Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...